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Abstract
Background: Measurement of albuminuria to stratify risk in chronic kidney disease (CKD) is not done universally in
the primary care setting despite recommendation in KDIGO (Kidney Disease Improving Global Outcomes)
guidelines. Pharmacist medication therapy management (MTM) may be helpful in improving CKD risk stratification
and management.
Methods: We conducted a pragmatic, cluster-randomized trial using seven primary care clinic sites in the Geisinger
Health System to evaluate the feasibility of pharmacist MTM in patients with estimated glomerular filtration rate
(eGFR) 45–59 ml/min/1.73 m2 and uncontrolled blood pressure (≥150/85 mmHg). In the three pharmacist MTM
sites, pharmacists were instructed to follow a protocol aimed to improve adherence to KDIGO guidelines on testing
for proteinuria and lipids, and statin and blood pressure medical therapy. In the four control clinics, patients
received usual care. The primary outcome was proteinuria screening over a follow-up of 1 year. A telephone survey
was administered to physicians, pharmacists, and patients in the pharmacist MTM arm at the end of the trial.
Results: Baseline characteristics were similar between pharmacist MTM (n = 24) and control (n = 23) patients,
although pharmacist MTM patients tended to be younger (64 vs. 71 y; p = 0.06) and less likely to have diabetes
(17 % vs. 35 %; p = 0.2) or baseline proteinuria screening (41.7 % vs. 60.9 %, p = 0.2). Mean eGFR was 54 ml/min/1.
73 m2 in both groups. The pharmacist MTM intervention did not significantly improve total proteinuria screening at
the population level (OR 2.6, 95 % CI: 0.5–14.0; p = 0.3). However, it tended to increase screening of previously
unscreened patients (78.6 % in the pharmacist MTM group compared to 33.3 % in the control group; OR 7.3, 95 %
CI: 0.96–56.3; p = 0.05). In general, the intervention was well-received by patients, pharmacists, and providers, who
agreed that pharmacists could play an important role in CKD management. A few patients contacted the research
team to express anxiety about having a CKD diagnosis without prior knowledge.
Conclusions: Pharmacist MTM may be useful in improving risk stratification and management of CKD in the
primary care setting, although implementation requires ongoing education and multidisciplinary collaboration and
careful communication regarding CKD diagnosis. Future studies are needed to establish the effectiveness of
pharmacist MTM on slowing CKD progression and improvement in cardiovascular outcomes.
(Continued on next page)
* Correspondence: achang@geisinger.edu
1Division of Nephrology, Geisinger Health System, 100 N Academy Ave,
Danville, PA 17821, USA
2Kidney Health Research Institute, Geisinger Health System, 100 N Academy
Ave, Danville, PA 17821, USA
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chang et al. BMC Nephrology  (2016) 17:168 
DOI 10.1186/s12882-016-0383-7
(Continued from previous page)
Trial registration: ClinicalTrials.gov, NCT02208674
Registered August 1, 2014, first patient enrolled September 30, 2014
Keywords: Pharmacist medication therapy management, Chronic kidney disease, Albuminuria, Proteinuria,
Screening, KDIGO guidelines
Background
Chronic kidney disease (CKD) affects one in seven adults
in the U.S. and is estimated to account for more than
20 % of annual Medicare expenditures [1, 2]. Optimal
screening and treatment strategies for CKD have been rec-
ommended by KDIGO (Kidney Disease: Improving Global
Outcomes). For example, guidelines recommend using
both estimated glomerular filtration rate (eGFR) and
quantification of albuminuria (or proteinuria) to stratify
renal and cardiovascular risk in CKD patients [3–5]. For
patients with non-proteinuric CKD, KDIGO guidelines
recommend treatment to a blood pressure goal of ≤140/90.
For patients with proteinuric CKD, KDIGO guidelines
recommend a lower blood pressure goal of ≤130/80,and
the use of angiotensin converting enzyme inhibitors
(ACEIs) or angiotensin receptor blockers (ARBs) [3].
KDIGO guidelines also recommend treatment with statins
for all adults ≥ 50 years with CKD, regardless of proteinuria
status [3, 6].
Despite these recommendations, adherence to CKD
guidelines is low; for instance, proteinuria screening
rates in CKD patients range from 10 to 45 % across dif-
ferent health systems. [7–10] Similar deficiencies in
CKD guideline adherence have been reported for
achievement of optimal blood pressure goals [7–9], pre-
scription of indicated ACEIs and ARBs [11–13], and pre-
scription of statin therapy [14, 15]. Primary care
providers manage the majority of CKD patients and
often do not list CKD as a problem list diagnosis [8].
Thus, effective interventions, delivered in the primary
care setting, are needed to improve screening and treat-
ment for CKD.
Pharmacist medication therapy management (MTM)
has been shown to be effective in treating hypertension
[16, 17], diabetes [18], and CKD-related anemia [19]. We
performed a pilot, cluster-randomized trial of outpatient
primary care clinics to examine the feasibility of using
pharmacist MTM to improve proteinuria screening and
CKD management in a large, integrated health system.
Methods
The pilot study was a prospective 2-arm, cluster-
randomized pragmatic trial, funded by Geisinger Clinic.
We recruited participants from seven primary care clinic
sites at Geisinger, a large integrated health system that
includes 43 community practice clinic sites across
central and northeastern Pennsylvania and an extensive
pharmacist-led MTM program. The Geisinger Clinic
institutional review board (IRB Number 2014-0251)
approved the protocol. A modified informed consent
process was utilized, which entailed full disclosure and
explanation to eligible patients (delivered by mail) and
to participating providers (by email) at the primary care
sites. Eligible patients were asked to respond within
7 days if they wished not to participate; if no response
was received participation was assumed. Health care
providers were informed of their patients’ participation
in the study.
Study population
Trial participants were adults actively receiving primary
care with Geisinger Health Plan insurance at one of the
7 Geisinger primary care clinic sites with eGFR between
45 and 59 ml/min/1.73 m2 and uncontrolled blood pres-
sure (mean blood pressure over past year ≥ 150/85). To
ensure that patients were regularly receiving care at
Geisinger, we only included those who had at least two
outpatient blood pressure measurements within the last
12 months, and a serum creatinine scheduled within the
next 30 days. Exclusion criteria included hospitalization
in the past year or positive pregnancy test during the
past 12 months. The first participants were enrolled into
the study in September 2014 and the last participant
finished the study in February 2016.
Participant flow
We utilized a cluster randomized design, with primary
care sites at Geisinger defined as the cluster unit. From
a total of 43 primary care clinic sites, an initial six sites
were selected based on the presence of an MTM
pharmacist on site and similar numbers of patients, phy-
sicians and physician assistants. These six initial clinic
sites were randomized 1:1 using a computer program
into the pharmacist MTM or a control arm. A 7th clinic
site was added in December 2015 due to slow recruit-
ment in the control arm. We used the electronic health
record (EHR) to identify eligible patients.
Pharmacist MTM and control arms
All Geisinger clinics include a pharmacist trained in the
management of common chronic conditions, such as
dyslipidemia, diabetes, and hypertension. Training for
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hypertension management included a lecture from a
hypertension expert, 8 week self-study of hypertension
training modules, clinician shadowing, and an annual
hypertension competency exam. The approach to hyper-
tension management included assessing medication
adherence, lifestyle modification (Dietary Approaches to
Stop Hypertension dietary pattern and weight loss for
those overweight/obese, exercise >30 min 5×/week),
medication initiation/titration according to Journal of
the American Medical Association (JAMA) Hyperten-
sion 2014 guidelines [20], and appropriate dosing of
medications according to renal function. Under a collab-
orative practice agreement between pharmacists and
providers, pharmacists were authorized to prescribe and
titrate antihypertensive medications.
Patients in the control clinics did not receive any
additional care for this study although all primary care
providers received a lecture and brief written summaries
about KDIGO guideline-based CKD risk stratification
and management before the study began [3]. Patients in
the clinics randomized to the pharmacist MTM arm
received additional support from the pharmacist at the
clinic site. These pharmacists received additional educa-
tion about KDIGO-based screening and management
guidelines for proteinuria, blood pressure and lipids in a
one-on-one session with a nephrologist, who maintained
communication with pharmacists regularly to answer
any questions and discuss management. These pharma-
cists received a list of the study participants and were
instructed to review charts, order lipid and urine albu-
min/creatinine ratio (ACR) screening tests, and manage
blood pressure and lipid therapy according to KDIGO
guidelines. In general, patients were contacted by tele-
phone if they needed proteinuria screening completed,
and if needed, were scheduled for clinic visits with the
pharmacist for medication initiation and/or titration. If
patients had completed proteinuria screening within the
past 12 months and the most recent outpatient blood
pressure reading in the EHR was within target range, no
contact was made with the patient. Selection and titra-
tion of antihypertensive medications was based on
JAMA 2014 Hypertension Guidelines [20], but to
KDIGO 2012 target blood pressure goals [3]. Once the
blood pressure goal was achieved, the patient was dis-
charged from the pharmacists’ care.
Outcomes
The primary study outcome was screening for protein-
uria by urine ACR or protein/creatinine ratio (PCR)
within 1 year of the enrollment date. Exploratory out-
comes included screening for hyperlipidemia within
1 year of the enrollment date, end-of-trial statin treat-
ment, achievement of blood pressure goals (<140/90 for
non-proteinuric CKD and <130/80 for proteinuric CKD;
patients with no proteinuria data were assumed to be
non-proteinuric), and treatment with ACEI or ARBs for
proteinuric CKD. Outcomes were ascertained by extrac-
tion of EHR data and chart review. Blood pressure out-
comes were assessed by averaging all outpatient clinic
blood pressure readings up to 1 year after the enroll-
ment date. Proteinuric CKD requiring more aggressive
BP goal and ACE/ARB therapy was defined as ACR ≥
30 mg/g for patients with diabetes and ACR ≥ 300 mg/g
for patients without diabetes, per KDIGO guidelines [3].
Protein/creatinine ratio values (g/g) were converted to
urine albumin/creatinine ratios (mg/g) by dividing pro-
tein/creatinine ratios by 0.0017566 if female and dividing
by 0.002655 if male [21].
Questionnaires
At the end of the study, we administered telephone sur-
veys of patients, providers, and pharmacists to assess the
acceptability of the pharmacist MTM intervention.
Patients were asked about the effectiveness of the
pharmacist in providing kidney care, their comfort level
with the pharmacist, and whether they wished to receive
further pharmacist care. Pharmacists were asked about
their confidence in managing blood pressure and lipids
in patients with CKD, how helpful they believed their
actions were for patients, and whether pharmacists
should play an active role in managing blood pressure,
lipids, and other aspects of CKD. Providers were asked
whether they were aware that the pharmacist was
managing some of their patients with CKD, and if so,
how confident and satisfied they were in the pharmacists
managing blood pressure and lipid-lowering medica-
tions. Providers were also asked whether pharmacists
should play an active role in managing blood pressure,
lipids, and other aspects of CKD.
Other variables of interest
We used data from the clinic visit closest to the enroll-
ment date to determine baseline characteristics includ-
ing age, gender, systolic blood pressure, diastolic blood
pressure, serum creatinine, smoking status, use of statin,
angiotensin converting enzyme inhibitor (ACEI), and
angiotensin receptor blocker (ARB) medications, and
International Classification of Diseases, Ninth Revision
(ICD-9) diagnoses of hypertension, diabetes, coronary
artery disease, dyslipidemia, and heart failure.
Analytic considerations
Assuming proteinuria screening rates of 30 % in the
control group and 80 % in the intervention group, we
estimated that a sample size of 72 patients would give
us > 80 % power to detect a difference in screening rates
between study arms at an alpha level of 0.05 with a
small-moderate intracluster correlation coefficient.
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Descriptive statistics including mean and standard
deviations for continuous variables, and frequency
percentages for categorical variables are presented.
Demographic and clinical characteristics between the
MTM and the control arms were compared using t-test
and chi-squared tests for continuous and categorical
data, respectively. We used random effects logistic
regression to determine the effects of pharmacist MTM
on each outcome in the total population. For the pro-
teinuria screening outcome, we conducted a subgroup
analysis only including patients who were unscreened at
baseline, accounting for the clustered design. We also
conducted sensitivity analyses, adjusting for differences
in baseline age, diabetes, and adherence to the particular
outcome. For the proteinuria screening outcome, this
analysis only included the previously unscreened sub-
group, and only adjusted for age as all patients with
diabetes successfully achieved this outcome.
All analyses were performed using SAS Statistical
Software (v9.4, SAS Institute, Inc. Cary, NC).
Results
There were 73 patients eligible for the study (45 in
clinics randomized to the pharmacist MTM, 28 in con-
trol clinics) who were contacted from September 2014
to February 2015. Of the 73 eligible patients, 26 patients
(pharmacist MTM 21, control 5) opted out of the study
prior to any intervention, leaving 24 pharmacist MTM
patients and 23 control patients with data for analysis
(Fig. 1). Of the 24 pharmacist MTM patients, a total of
15 (62.5 %) patients were contacted by telephone and 7
(29.2 %) also had in-person visits with a pharmacist for
the trial. Among those who received telephone calls, the
median [interquartile range (IQR)] number of telephone
calls was 1 (1, 3). Among those who had in-person visits,
the median (IQR) number of visits was 2 (1, 9). Midway
through the trial, the principal investigator left the insti-
tution, and an interim analysis was conducted to deter-
mine whether to continue recruitment. After review of
preliminary data, the remaining study team did not be-
lieve additional information would be gained from this
pilot study, and recruitment was stopped.
Baseline characteristics
Patients in the control group tended to be older (control
70.6 y, intervention 64.0 y; p = 0.06), and more likely to
have an ICD-9 diagnosis of diabetes (control 35 %, inter-
vention 17 %; p = 0.2) (Table 1). Otherwise, groups were
similar in terms of prevalence of ICD-9 diagnoses of
hypertension (control 96 %, intervention 92 %; p = 0.6),
Primary care clinic sites in Geisinger (n=43)
Selected primary care clinic sites based on similar provider characteristics (n=6)
Site randomized to control (n=3)
Additional site added to control due to low recruitment (n=1)
Sites randomized to pharmacy MTM (n=3)
Patients eligible for enrollment (n=28)
Opted out (n=5)
Patients included in analysis(n=23)
Primary outcome data available (n=23)
Patients eligible for enrollment (n=45)
Opted out (n=21)
Patients included in analysis (n=24)
Primary outcome data available (n=24)
Questionnaires completed by patients (14/24)
Fig. 1 Study flow diagram
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dyslipidemia (control 74 %, intervention 67 %; p = 0.6),
coronary artery disease (control 17 %, intervention 21 %;
p = 0.8), and congestive heart failure (0 % in both
groups). Mean baseline eGFR was similar in both groups
(54 ml/min/1.73 m2; p = 0.9), as was systolic blood
pressure (control 142 mmHg, intervention 145 mmHg;
p = 0.6), diastolic blood pressure (control 78 mmHg,
intervention 81 mmHg; p = 0.4), use of ACEI or ARB
medications (control 78 %, intervention 71 %; p = 0.6),
and use of statin medications (control 70 %, intervention
54 %; p = 0.3). At baseline, 24/47 (50.1 %) of the patients
already met the proteinuria screening goal, 19/47
(40.4 % already met blood pressure goals, and 44/47
(93.6 %) already met lipid screening goals.
Effect of pharmacist MTM on proteinuria and lipid
screening
At the baseline visit, 10/24 (41.7 %) of the pharmacist
MTM and 14/23 (60.9 %) in the control group had
already achieved the proteinuria screening goal (p = 0.2).
At the end of the trial, proteinuria screening was not sig-
nificantly different between the pharmacist MTM group
and the control group (87.5 % vs. 73.9 %; OR 2.6, 95 %
CI: 0.47–14.0; p = 0.3). However, among patients who
were previously unscreened, 11/14 (78.6 %) in the
pharmacist MTM group and 3/9 (33.3 %) in the control
group completed proteinuria screening (OR 7.3, 95 %
CI: 0.96–56.3; p = 0.05) (Table 2). Findings in the
previously unscreened subgroup remained consistent
after adjustment for age, (OR 15.0, 95 % CI: 1.1–201.7;
p = 0.04). The proportion of patients who completed
lipid screening increased from 87.5 to 100 % in the
pharmacist MTM group; all patients in the control
group had already completed lipid screening at baseline.
Effect of pharmacist MTM on blood pressure and lipid
management
Pharmacist MTM had no significant effect on blood
pressure control or statin therapy (Table 2). The propor-
tion of patients in the pharmacist MTM group who
achieved their blood pressure goal was 42 % at baseline
and 54 % at the end of the trial compared to 39 % at
baseline and 57 % at the end of the trial in the control
group (OR 0.9, 95 % CI: 0.2–3.0, p = 0.9). Findings were
consistent when adjusted for differences in baseline
characteristics (OR 0.7, 95 % CI: 0.2–2.6; p = 0.5). The
pharmacist MTM intervention also had no significant
effect on statin therapy (OR 0.4, 95 % CI: 0.1–1.3; p = 0.1);
the proportion of patients in the pharmacist MTM group
who were on statins was 54 % at baseline and 50 % at the
end of the trial compared to 70 % at baseline and 74 % at
the end of the trial in the control group. Results were
largely unchanged after adjustment for baseline character-
istics (OR 0.2, 95 % CI: 0.02–2.4; p = 0.2). The proportion
of proteinuric CKD patients taking an ACEI or ARB in-
creased from 2/4 (50 %) at baseline to 4/4 (100 %) at the
end of the trial in the pharmacist MTM group; 3/3
(100 %) patients in the control group were taking an ACEI
or ARB at the beginning and the end of the trial. Orders
written by pharmacists in the pharmacist MTM arm in-
cluded urine albumin/creatinine ratios (14), lipid profiles
(1), statin medications (5), ACEI or ARB medications (3),
and other blood pressure medications (2).
Acceptability of pharmacist MTM
A total of 14/24 (58.3 %) of patients, 9/9 (100 %) of
primary care providers, and 4/4 (100 %) pharmacists of
the three intervention clinic sites answered end-of-study
surveys. Only 6/14 (43 %) patients recalled having
contact with a pharmacist during the trial; these patients
in general were very satisfied with the care they received,
felt better-informed about kidney health, and were inter-
ested in receiving future pharmacist care (Table 3). All
four pharmacists felt at least somewhat comfortable with
managing blood pressure and lipids although one of the
4 pharmacists did not feel that adequate CKD training
was provided (Table 4). All pharmacists agreed that
pharmacists could play an important role in helping
Table 1 Baseline characteristics
Control (n = 23) Pharmacist MTM (N = 24)
Age, y 70.6 (9.7) 64.0 (13.2)
Female, % 52.2 % 62.5 %
SBP, mmHg 142.3 (16.4) 145.1 (19.7)
DBP, mmHg 77.7 (11.4) 81.3 (15.1)
eGFR, ml/min/1.73 m2 53.8 (5.8) 54.1 (7.7)
Current smoker, % 4.3 % 8.3 %
Hypertension, % 95.6 % 91.7 %
Diabetes, % 34.8 % 16.7 %
Coronary artery disease, % 17.4 % 20.8 %
Dyslipidemia, % 73.9 % 66.7 %
Heart Failure, % 0 % 0 %
Taking ACEI/ARB, % 78.3 % 70.8 %
Taking statin, % 69.6 % 54.2 %
ACR categorya, %
<30 mg/g 47.8 % 62.5 %
30–299 mg/g 26.1 % 20.8 %
> = 300 mg/g 4.4 % 4.2 %
Missing 21.7 % 12.5 %
aACR category reflects urine ACR and protein/creatinine ratio values
measured during baseline or during the trial for individuals missing
baseline data (n = 23). Protein/creatinine ratio values (g/g) were converted
to urine albumin/creatinine ratios (mg/g) by dividing protein/creatinine
ratios by 0.0017566 if female and dividing by 0.002655 if male
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, eGFR
estimated glomerular filtration rate, ACEI angiotensin converting enzyme
inhibitor, ARB angiotensin receptor blocker, ACR albumin/creatinine ratio
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manage blood pressure, lipids, and other aspects of
CKD. Of the nine primary care providers, only 5 (56 %)
reported being aware that their clinic site pharmacist
was actively managing some of their CKD patients.
There was some variability on whether providers agreed
with changes made by the pharmacist during the study
(2 strongly agreeing, 1 somewhat agreeing, 3 neutral, 1
somewhat disagreeing, 2 no response) (Table 5). How-
ever, most providers reported feeling comfortable with
pharmacists managing blood pressure and lipids in their
patients, and thought that pharmacists could be helpful
in managing other aspects of CKD.
Discussion
In this pilot study, we evaluated the feasibility of con-
ducting a pharmacist-based intervention to improve ad-
herence to KDIGO guideline-based clinical practice.
One of the notable lessons was that adherence to some
guidelines was already fairly good at baseline (protein-
uria screening 50.1 %; achievement of blood pressure
goal 40.4 %; lipid screening 93.6 %; use of ACEI/ARB for
proteinuric CKD 71.4 %). Indeed our pharmacist
intervention was effective in improving proteinuria
screening only in previously unscreened patients, and we
were not powered to show significant differences in
blood pressure or statin treatment outcomes. Still, our
pilot study provides valuable insights in conducting a
pragmatic randomized trial in a health system, and sug-
gests that pharmacist MTM to provide CKD care is feas-
ible and generally well-accepted by patient, pharmacists,
and providers.
A few studies have examined the use of non-physician
providers in addition to nephrologists to improve man-
agement of CKD. A randomized trial of 474 patients
with CKD in Canada found no benefit of nurse-
coordinated care in collaboration with a nephrologist
versus usual care, on eGFR decline or controlling risk
factors [22]. Initial results from a randomized trial of
788 patients in the Netherlands found no effect of nurse
practitioner support, in addition to nephrologist care, on
cardiovascular risk or renal outcomes [23]. However, ex-
tended follow-up analysis of this trial found that nurse
practitioner support decreased risk of a combined renal
outcome (doubling of creatinine, ESRD or death) by
20 % [24]. Recently, a randomized pragmatic trial of
Table 2 Study outcomes pre- and post-intervention
Control (n = 23) Pharmacist MTM (n = 24)
Baseline End-of-trial Baseline End-of-trial OR (95 % CI) P value
Proteinuria screeninga 14 (60.9 %) 17 (73.9 %) 10 (41.7 %) 21 (87.5 %) Entire population: 2.6 (0.5–14.0)
Previously unscreened subgroup:
7.3 (0.96–56.3)
Entire population: 0.3 Previously
unscreened subgroup: 0.05
Lipid screening 23 (100 %) 23 (100 %) 21 (87.5 %) 24 (100 %) N/A N/A
Treatment with statin 16 (69.6 %) 17 (73.9 %) 13 (54.2 %) 12 (50.0 %) 0.4 (0.1–1.3) 0.1
Achieved BP goal 9 (39.1 %) 13 (56.5 %) 10 (41.7 %) 13 (54.2 %) 0.9 (0.3–3.0) 0.9
aRandom effects logistic regression was used to determine the effects of pharmacist MTM on proteinuria screening in the entire population, and then just among
patients who were unscreened at baseline, accounting for the clustered design
Table 3 Patient survey
Question Score (SD)a
I was comfortable receiving care from a Pharmaciset
to help manage my blood pressure, lipids, and
kidney health
1 (0)
I trusted the Pharmacist and followed his/her
instructions as I would follow from the doctor
1.2 (0.4)
The Pharmacist was able to answer all of my questions
about the management of my blood pressure, lipids,
and kidney health
1.2 (0.4)
I felt more informed about kidney health after meeting
with the Pharmacist
1.8 (1.6)
I felt that receiving care from a Pharmacist was beneficial
to my health
1 (0)
I would like to receive more Pharmacist attention in
addition to my routine care
1.2 (0.4)
A total of 14/24 (58.3 %) patients in the intervention arm completed the
survey although only six patients remembered talking with the pharmacist. All
6 of these patients completed all survey questions
aScore – ranged from 1 to 5 (1 strongly agree, 2 somewhat agree, 3 neutral, 4
somewhat disagree, 5 strongly disagree)
Table 4 Pharmacist survey
Question Score (SD)a
I was comfortable providing care to patients with CKD 2.3 (1.3)
I felt that I received adequate training in order to
effectively manage blood pressure and lipids in
patients with CKD
2.3 (1.9)
I felt comfortable in my ability to manage blood pressure
and lipids in patients with CKD
1.5 (0.6)
I felt that patients were following my recommendations 2.3 (0.5)
I felt that my actions were beneficial to the patients 2 (0.8)
I think that pharmacists can play an important role in
helping manage blood pressure and lipids in patients
with CKD
1.3 (0.5)
In my opinion, pharmacists can be helpful in managing
other aspects of CKD beyond blood pressure and lipids
1.3 (0.5)
All 4/4 of pharmacists in the pharmacist MTM arm completed all
survey questions
aScore – ranged from 1-5 (1 strongly agree, 2 somewhat agree, 3 neutral, 4
somewhat disagree, 5 strongly disagree)
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2199 veterans found that a telephone-based pharmacist
intervention improved CKD-related lab testing and in-
creased the number of antihypertensive medications pre-
scribed, but had no significant effect on blood pressure
[25]. However, pharmacists in this study were limited to
one-time telephone contacts with patients and could
only recommend medication changes to primary care
providers.
Variability in the success of team-based approaches on
blood pressure control may be due to differences in the
intervention, study population, and access to nephrology
care. Important intervention characteristics to consider
include the intensity of the intervention, the ability of
non-physicians to order medications, and the method by
which blood pressure is measured. Recent randomized
trials utilizing home blood pressure monitoring, deliv-
ered by pharmacists, have demonstrated success in
achieving improvements in blood pressure control [16, 17].
Whether or not these successes can be translated to
patients with CKD, who are among the most difficult to
control, remains to be seen.
There were several valuable lessons learned during this
pilot study that may help inform conducting future
pragmatic trials in health systems. Many patients initially
included in the study met their blood pressure and other
KDIGO goals at their most recent appointment, and did
not receive any specific pharmacist MTM intervention.
However, blood pressure readings can vary substantially,
and some of these controlled patients later had blood
pressure readings higher than their goal range. Use of
real-time registry data may assist pharmacists/providers
in tracking blood pressure readings over time and inter-
vening when appropriate. Some providers and pharma-
cists questioned the appropriateness of following
KDIGO guidelines that conflicted with 2013 ACC/AHA
lipid guidelines [26] and JAMA 2014 blood pressure
guidelines [20]. We speculate that confusion over differ-
ent guidelines may impact the success of implementing
more stringent KDIGO recommendations for blood
pressure and statin treatment in patients with CKD.
Recent publication of the SPRINT trial, showing benefits
of a systolic blood pressure goal < 120 mmHg in non-
diabetic patients at high cardiovascular risk, will likely
impact blood pressure guidelines [27]. Ongoing educa-
tion and multidisciplinary discussion is needed to estab-
lish consensus target goals and optimize management of
patients with CKD.
An unexpected complication of the trial was patient
concern created by the ‘opt-out’ letter mailed to eligible
patients during the early phase of the trial. While
actively receiving care, several patients were not aware
that they had CKD. The reasons for the lack of aware-
ness cannot be identified. However, it seems likely that
providers are either not recognizing or prioritizing
moderate CKD, and thus may not have educated their
patients about this condition. It is also important that
future pragmatic trialists utilizing a similar, modified
informed consent process recognize the possibility of
disease unawareness amongst eligible patients. As a re-
sult of the opt-out process, there may have been selec-
tion bias as more patients in the pharmacist MTM arm
opted out of the study compared to patients in the con-
trol arm. Future pragmatic trials trying to optimize CKD
management should consider altering the study design
(e.g. delayed randomization), such that waived consent is
acceptable to the IRB, provided risk is minimal. This
would help prevent selection bias that may have
occurred by patients opting out of the research study.
Considering concerns about lack of representativeness in
past trials and the desire to demonstrate real-world
effectiveness, pragmatic trials will likely become more
and more common in the future [28].
There were limitations in our small pilot study. Cluster
randomization of a small number of clinics resulted in
some marginal differences in baseline age and diabetes
status and recruitment was stopped early; however, the
goal of the study was less about efficacy and more about
identifying potential barriers for a full pragmatic trial.
Perhaps the most important result from this pilot study
was that power may be a significant concern – many
patients were already adherent to KDIGO screening and
management guidelines. A full pragmatic trial may
require a system-wide intervention, or even involvement
of multiple health systems. Utilization of other health-
care staff or automated ordering in risk stratifying CKD
patients may be needed to optimize healthcare re-
sources. Another limitation was that blood pressure was
measured routinely in clinic and not standardized. A
Table 5 Provider survey
Question Number (%) or
Score (SD)a
No response
I was comfortable with the Pharmacist
managing blood pressure and
cholesterol-lowering medication.
1.5 (0.9) 1 (11.1 %)
I agreed with the changes that were made
by the Pharmacist during this study.
2.4 (1.1) 2 (22.2 %)
I was satisfied having extra help from the
Pharmacist in managing conditions in
patients with CKD.
1.7 (1.0) 2 (22.2 %)
I felt that this program was beneficial to
the patients with regards to CKD
management.
1.9 (1.1) 2 (22.2 %)
I think that Pharmacists could be helpful
in managing other aspects of CKD
beyond blood pressure and lipids.
1.4 (0.7) 0
All 9/9 of providers completed the survey. However, only 5/9 (56 %) reported
being aware that a pharmacist was assisting with the management of some of
their CKD patients
aScore – ranged from 1 to 5 (1 strongly agree, 2 somewhat agree, 3 neutral, 4
somewhat disagree, 5 strongly disagree)
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future pragmatic trial involving blood pressure as a
major outcome needs to standardize clinic blood pres-
sure readings in a way that minimizes interruptions to
clinic workflow, and may want to consider utilizing
home blood pressure monitoring. Although the vast ma-
jority of patients reported high levels of satisfaction with
the pharmacist MTM arm, there was a higher rate of
opt-out in this arm, which may have resulted in more
compliant patients in the pharmacist MTM arm. Our
study population was limited to a mostly white, rural
population in an integrated health system; thus, results
may not be generalizable to other populations. On the
other hand, our pragmatic study design in an integrated
health system represents a strength. The intervention
was easily implementable given the infrastructure at
Geisinger where pharmacists are available at all primary
care clinic sites and already actively managing diabetes,
anticoagulation, and hypertension. Both pharmacists and
providers expressed considerable enthusiasm for extend-
ing management to include more aspects of CKD care.
Future pragmatic trials involving pharmacists may want
to incorporate other dimensions of CKD care, such as
CKD-related drug safety.
Conclusion
In conclusion, pharmacist MTM improved proteinuria
screening in previously unscreened patients with CKD,
and was generally well-received by patients, pharmacists,
and providers. Future research is needed to examine
whether pharmacist MTM could improve KDIGO
guideline adherence and CKD patient outcomes.
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